Showing results (131-140 of 242) with videos related to

Sort By:
Pageof 25
Gynecologic Oncology|October 5, 2014
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trialChee Khoon Lee, Sarah Lord, Tami Grunewald, et al.
Clinical & Experimental Optometry|January 22, 2026
Dose-dependent neurotoxic chemotherapy and corneal nerve morphological changesJeremy Chung Bo Chiang, Dimitra Makrynioti, David Goldstein, et al.
Future Oncology (London, England)|September 6, 2022
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)Panagiotis A Konstantinopoulos, Antonio Gonzalez-Martin, Felipe Melo Cruz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervixKosei Hasegawa, Shoji Nagao, Masanori Yasuda, et al.
Therapeutic Advances in Medical Oncology|December 17, 2021
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trialJean-Pierre Ayoub, Hans Wildiers, Michael Friedlander, et al.
British Journal of Cancer|May 13, 2021
Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agentsXing Xu, Yao Wang, Nicole S Bryce, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2021
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trialBanu K Arun, Hyo S Han, Bella Kaufman, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Pageof 25